The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary experience of ex-vivo expanded allogeneic universal donor TGFβi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo - STING trial.
 
Mark A. Ranalli
No Relationships to Disclose
 
Nilay Shah
Honoraria - Bayer; Fennec Pharma
Research Funding - Exelixis (Inst)
 
Micah Skeens
No Relationships to Disclose
 
Keri A. Streby
Honoraria - United Therapeutics
Consulting or Advisory Role - Innervate RAdiopharmaceuticals
Research Funding - United Therapeutics (Inst)
 
Margaret Lamb
Research Funding - Kiadis Pharma (Inst)
 
Lindsay A. Cole
No Relationships to Disclose
 
Dean Anthony Lee
Stock and Other Ownership Interests - Avidicure
Consulting or Advisory Role - Avidicure; Kiadis Pharma
Research Funding - Avidicure; Kiadis Pharma
Patents, Royalties, Other Intellectual Property - Over a dozen patent families involving NK cell therapeutics licensed to Kiadis Pharma through Nationwide Children's Hospital.
Travel, Accommodations, Expenses - Cyto-Sen Therapeutics; Merck Sharp & Dohme; Shire